• A diagnosis of advanced and unresectable or metastatic pancreatic adenocarcinoma confirmed by:

∙ Histopathology from primary tumor in pancreas, OR

‣ Histopathology from a non-pancreatic lesion in the presence of a mass in the pancreas consistent with pancreatic adenocarcinoma or a medically documented history of pancreatic adenocarcinoma.

• Measurable disease per RECIST v.1.1

• Male or non-pregnant, non-lactating female, ≥18 years or age

∙ If a female patient is of child-bearing potential, as evidenced by menstrual periods, she must have a negative serum pregnancy test (beta-human chorionic gonadotropin \[β- hCG\]) documented prior to the first administration of stud drugs

‣ Female patients of childbearing age and women \< 12 months since the onset of menopause must agree to use acceptable contraceptive methods for the duration of the study and 9 months following the last injection of OT-101.

‣ Male patients must use effective contraception for a duration of 6 months after the final dose, as per the prescribing information for oxaliplatin.

• Provide signed written informed consent

• Eastern Cooperative Group (ECOG) Performance Status (PS) score of 0-1

• Willingness and ability to comply with study requirements

• Patient has adequate organ function by the following laboratory assessments at baseline(obtained ≤28 days prior to Randomization):

• Hematologic

⁃ Platelets ≥100×109/L

⁃ Hemoglobin ≥9.0 g/dL

⁃ Absolute Neutrophil Count (ANC) ≥1.5×109/L

⁃ Patient has acceptable coagulation values obtained ≤28 days prior to Randomization as demonstrated by prothrombin time (PT) or international normalized ratio (INR) and partial thromboplastin time (PTT) ≤1.5× upper limit of normal (ULN) (if on Coumadin, patient must be changed to LMWH or on Factor II or Xa anticoagulant with a t½ of less than 24 hours

• Hepatic

⁃ Aspartate transaminase (AST)/alanine transaminase (ALT) ≤3×ULN (if liver metastases are present, ≤5×ULN)

⁃ Alkaline phosphatase ≤2.0×ULN (if liver metastases are present, ≤5×ULN)

⁃ Total bilirubin ≤2.0×ULN (in patients with Gilbert's Syndrome total bilirubin \< or = 2.5xULN)

• Renal

⁃ Calculated creatinine clearance ≥50 mL/min. Actual body weight should be used for calculating creatinine clearance (e.g., using the Modification of Diet in Renal Disease \[MDRD\] formula. For patients with a body mass index (BMI) \>30 kg/m2, lean body weight should be used instead

• Patient must have a life expectancy of ≥3 months in the opinion of the Investigator